DK3079669T3 - Sammensætninger med forsinket frigivelse af linaclotid - Google Patents

Sammensætninger med forsinket frigivelse af linaclotid Download PDF

Info

Publication number
DK3079669T3
DK3079669T3 DK14824655.6T DK14824655T DK3079669T3 DK 3079669 T3 DK3079669 T3 DK 3079669T3 DK 14824655 T DK14824655 T DK 14824655T DK 3079669 T3 DK3079669 T3 DK 3079669T3
Authority
DK
Denmark
Prior art keywords
linaclotide
delayed release
release compositions
compositions
delayed
Prior art date
Application number
DK14824655.6T
Other languages
English (en)
Inventor
Angelika Fretzen
Ahmad Hashash
Yun Mo
Anil Chhettry
Ritesh Sanghvi
Mohammad Mafruhul Bari
Andreas Grill
Matthew Miller
Mahendra Dedhiya
Mark G Currie
Original Assignee
Ironwood Pharmaceuticals Inc
Forest Laboratories Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52293217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3079669(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc, Forest Laboratories Holdings Ltd filed Critical Ironwood Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3079669T3 publication Critical patent/DK3079669T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
DK14824655.6T 2013-12-11 2014-12-11 Sammensætninger med forsinket frigivelse af linaclotid DK3079669T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914951P 2013-12-11 2013-12-11
US201361914952P 2013-12-11 2013-12-11
PCT/US2014/069838 WO2015089326A1 (en) 2013-12-11 2014-12-11 Delayed release compositions of linaclotide

Publications (1)

Publication Number Publication Date
DK3079669T3 true DK3079669T3 (da) 2020-11-02

Family

ID=52293217

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14824655.6T DK3079669T3 (da) 2013-12-11 2014-12-11 Sammensætninger med forsinket frigivelse af linaclotid

Country Status (28)

Country Link
US (7) US20160310560A1 (da)
EP (2) EP3821881A1 (da)
JP (4) JP6964380B2 (da)
KR (3) KR102337809B1 (da)
CN (3) CN106659687A (da)
AU (3) AU2014362220B2 (da)
CA (1) CA2933587C (da)
CL (1) CL2016001424A1 (da)
CY (1) CY1123953T1 (da)
DK (1) DK3079669T3 (da)
EA (1) EA201691216A1 (da)
EC (2) ECSP16059106A (da)
ES (1) ES2838007T3 (da)
HR (1) HRP20201753T1 (da)
HU (1) HUE052981T2 (da)
IL (2) IL246155A0 (da)
LT (1) LT3079669T (da)
MX (2) MX2016007625A (da)
NZ (2) NZ721952A (da)
PE (2) PE20211976A1 (da)
PH (1) PH12016501122A1 (da)
PL (1) PL3079669T3 (da)
PT (1) PT3079669T (da)
RS (1) RS61133B1 (da)
SG (2) SG10201804817TA (da)
SI (1) SI3079669T1 (da)
UA (1) UA119335C2 (da)
WO (2) WO2015089335A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016125064A1 (en) * 2015-02-02 2016-08-11 Aurobindo Pharma Ltd Stable compositions comprising linaclotide
EP3302440B1 (en) * 2015-06-05 2021-01-06 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
WO2017156214A1 (en) * 2016-03-11 2017-09-14 Gateway Pharmaceutical LLC Pharmaceutical compositions for colon-specific delivery
US11534404B2 (en) * 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
BR112019012689A2 (pt) * 2016-12-21 2019-11-19 Ironwood Pharmaceuticals Inc métodos de tratamento da síndrome do intestino irritável com formulações de linaclotide modificada ou de liberação prolongada
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
KR20210003759A (ko) * 2018-03-23 2021-01-12 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드 제형 및 위장관-특이적 전달을 위한 방법
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
MA56128A (fr) * 2019-06-10 2022-04-13 Ironwood Pharmaceuticals Inc Traitement de la douleur abdominale associée au syndrome du côlon irritable à diarrhée prédominante
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
CN110935007B (zh) * 2019-12-12 2023-06-23 烟台大学 利那洛肽复方组合物、制剂及其用途和制备方法
EP4340838A1 (en) * 2021-05-19 2024-03-27 Alberto Paz Orally administered compositions for cancer treatment
WO2024076577A1 (en) * 2022-10-03 2024-04-11 Brim Biotechnology, Inc. Compositions comprising pedf-derived short peptides (pdsp) and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN201252259Y (zh) * 2008-07-24 2009-06-03 富士康(昆山)电脑接插件有限公司 电连接器
CN102186490B (zh) * 2008-08-15 2015-07-29 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
CA2745694C (en) * 2008-12-03 2018-03-27 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
RU2012109415A (ru) * 2009-08-13 2013-09-20 Айронвуд Фармасьютикалз, Инк. Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы
TR201711271T4 (tr) * 2010-02-17 2019-02-21 Ironwood Pharmaceuticals Inc Gastrointestinal Bozukluklar İçin Tedaviler
PL2603232T3 (pl) * 2010-08-11 2020-05-18 Ironwood Pharmaceuticals, Inc. Stabilne formulacje linaklotydu
US20140162963A1 (en) * 2010-09-11 2014-06-12 Forest Laboratories Holdings Limited Treatment of Constipation-Predominant Irritable Bowel Syndrome
JP2012155108A (ja) * 2011-01-26 2012-08-16 Kyocera Document Solutions Inc 現像ローラ、現像装置および画像形成装置
CN104053449B (zh) * 2011-08-17 2016-12-07 硬木药品公司 胃肠疾患的治疗
WO2013047795A1 (ja) * 2011-09-30 2013-04-04 アステラス製薬株式会社 粒子状医薬組成物
US20140018307A1 (en) * 2012-07-12 2014-01-16 Forest Laboratories Holdings Ltd. Linaclotide compositions
CA2902348C (en) * 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням

Also Published As

Publication number Publication date
PL3079669T3 (pl) 2021-04-06
US20220031802A1 (en) 2022-02-03
NZ759512A (en) 2022-05-27
EP3079669A1 (en) 2016-10-19
US20200038476A1 (en) 2020-02-06
SG11201604729QA (en) 2016-07-28
SI3079669T1 (sl) 2021-01-29
CN115089556A (zh) 2022-09-23
UA119335C2 (uk) 2019-06-10
HUE052981T2 (hu) 2021-05-28
WO2015089335A1 (en) 2015-06-18
AU2020202319B2 (en) 2022-03-24
CA2933587A1 (en) 2015-06-18
JP6964380B2 (ja) 2021-11-10
AU2014362220B2 (en) 2020-04-30
AU2022201891A1 (en) 2022-04-07
PE20161373A1 (es) 2016-12-17
EP3821881A1 (en) 2021-05-19
CY1123953T1 (el) 2022-03-24
EP3079669B1 (en) 2020-09-30
MX2021011906A (es) 2021-10-26
US20160310559A1 (en) 2016-10-27
PH12016501122A1 (en) 2016-07-18
WO2015089326A1 (en) 2015-06-18
EA201691216A1 (ru) 2016-11-30
MX2016007625A (es) 2016-12-09
PT3079669T (pt) 2020-11-30
KR20230039764A (ko) 2023-03-21
JP2017504590A (ja) 2017-02-09
US20240075094A1 (en) 2024-03-07
JP2023126475A (ja) 2023-09-07
KR20160132001A (ko) 2016-11-16
CN106659687A (zh) 2017-05-10
US20160310560A1 (en) 2016-10-27
HRP20201753T1 (hr) 2020-12-25
ECSP16059106A (es) 2017-02-24
BR112016013419A2 (pt) 2017-09-26
AU2014362220A1 (en) 2016-06-30
JP2021113227A (ja) 2021-08-05
RS61133B1 (sr) 2020-12-31
CL2016001424A1 (es) 2017-09-08
US20180015139A1 (en) 2018-01-18
CA2933587C (en) 2023-09-26
US20170157200A1 (en) 2017-06-08
KR102337809B1 (ko) 2021-12-10
AU2020202319A1 (en) 2020-04-23
IL283012A (en) 2021-06-30
ECSP21072161A (es) 2021-11-18
SG10201804817TA (en) 2018-07-30
JP7483656B2 (ja) 2024-05-15
LT3079669T (lt) 2020-12-10
KR102509291B1 (ko) 2023-03-14
IL246155A0 (en) 2016-07-31
ES2838007T3 (es) 2021-07-01
PE20211976A1 (es) 2021-10-05
KR20210152588A (ko) 2021-12-15
CN112569199A (zh) 2021-03-30
JP2019073559A (ja) 2019-05-16
WO2015089326A9 (en) 2016-08-04
NZ721952A (en) 2022-05-27

Similar Documents

Publication Publication Date Title
IL283012A (en) Sustained release formulations of linclotide
DK2961766T3 (da) Kvantificering af vaccinesammensætninger
DK2845905T3 (da) Fremstilling af oligosaccharider
DK3611262T3 (da) Fremgangsmåder til sekvensering af immunrepertoire
DK2968529T3 (da) Fremstilling af jordnøddeformuleringer til oral desensibilisering
DK2970954T3 (da) Modifikation af polypeptider
DK3022217T3 (da) Sammensætninger til modulering af tau-ekspression
DK2984166T3 (da) Sammensætninger til behandling af mpsi
DK2961388T3 (da) Kombinationer af lægemidler
DK3027618T3 (da) Polymorf af syk-hæmmere
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
DK3068854T4 (da) Fjernelse af uønskede propanolbestanddele
DK3003485T3 (da) Sammensætning omfattende beta-casein a2 til anvendelse til forebyggelse af tarmbetændelse
DK2822568T3 (da) Anvendelser af caseinsammensætninger
DK3027750T3 (da) Biokatalytisk sammensætning
DK2919777T3 (da) Transmukosal afgivelse af tocotrienol
DK3021839T3 (da) Sammensætninger for behandling af fibrose
DK2956410T3 (da) Kompositsilicium- eller komposittinpartikler
DK2800572T3 (da) Sammensætning af ellagitannin-rige ekstrakter
DK3052101T3 (da) Konjugater af sn-38 med langsom frigivelse
DK2988728T3 (da) Reducering af partikelstørrelsen af en antimuscarin-forbindelse